Roche licenses new flu-fighting technology
WASHINGTON |
WASHINGTON Feb 8 (Reuters) - Roche AG's (ROG.VX) Genentech unit has licensed an experimental new technology that would use antibodies to fight influenza, including H1N1 swine flu, Harvard's Dana Farber Cancer Institute said on Monday.
Dana-Farber said it and the Sanford-Burnham Medical Research Institute signed a license agreement with Genentech giving the company exclusive rights to manufacture, develop and market human monoclonal antibodies to treat and protect against group 1 influenza viruses. (Reporting by Maggie Fox, editing by Gerald E. McCormick)
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters